Alkermes plc

Last updated
Alkermes plc
Company type Public
Industry Biotechnology
Founded1987;38 years ago (1987)
FounderMichael Wall
Headquarters
Dublin
,
Ireland [1]
Key people
Richard Pops (CEO)
RevenueIncrease2.svg US$1.1 billion (2022) [2]
Decrease2.svg US$-20.5 million
Decrease2.svg US$-158 million (2022)
Total assets Increase2.svg US$1.9 billion
Total equity Increase2.svg US$1 billion
Number of employees
2,100
Website www.alkermes.com

Alkermesplc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. [3] In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. [4] The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio. [1]

Contents

Products

Alkermes has four proprietary commercial drug products [5] approved for the treatment of schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.

Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia. [6] [7]

In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, alixorexton, previously known as ALKS 2680. Alixorexton is in development for the treatment of narcolepsy and idiopathic hypersomnia. [8]

In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa. [9]

In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo Nordisk. [10]

In April 2025, Alkermes announced the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia. [11]

In July 2025, Alkermes announced positive topline results from Vibrance-1, a phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1. [12]

References

  1. 1 2 Robert Weisman (10 May 2011). "Alkermes to buy Irish drug maker". Boston Globe.
  2. ↑ "Alkermes PLC".
  3. ↑ "Alkermes And Richard Pops — The Evolution Of A Company And Its Leader". LifeScienceLeader.com. 1 May 2019. Retrieved 21 June 2019.
  4. ↑ "Alkermes Reels In Elan's Drug Technology Business". Forbes.com. 9 May 2011. Retrieved 13 October 2011.
  5. ↑ "Alkermes, Inc. Company Information". Drugs.com. Retrieved 2023-11-22.
  6. ↑ "U.S. Third-Party Medicines | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  7. ↑ "Alkermes EU Pharmaceutical Manufacturing Products | Alkermes". www.alkermes.com. Retrieved 2023-11-22.
  8. ↑ "Orexin Receptor ALKS 2680 Demonstrates Positive Phase 1 Findings". Neurology live. 2023-11-06. Retrieved 2023-11-22.
  9. ↑ "Alkermes separates cancer drug business as new company Mural". BioPharma Dive. Retrieved 2023-11-22.
  10. ↑ "Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk". alkermes.com. 2024-05-02. Retrieved 2024-06-24.
  11. ↑ "Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia". Alkermes plc. April 1, 2025. Retrieved April 15, 2025.
  12. ↑ "Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1a". Alkermes plc. July 21, 2025. Retrieved July 30, 2025.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.